| NRX PHARMACEUTICALS |
| USA |
| Gesundheit |
| US6294442099 / A4091K |
| B1Q (Frankfurt) / NRXP (NASDAQ) |
| FRA:B1Q, ETR:B1Q, B1Q:GR, NASDAQ:NRXP |
| - |
| https://www.nrxpharma.com.. |
|
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on severe depression, bipolar depression, post-traumatic stress disorder, and related suic..
>Volltext.. |
| 104.8 Mio. EUR |
| 82.44 Mio. EUR |
| 3.04 Mio. EUR |
| -17.47 Mio. EUR |
| -21.05 Mio. EUR |
| -0.66 EUR |
| 1.12 Mio. EUR |
| 23.92 Mio. EUR |
| -17.73 Mio. EUR |
| 0.79 |
| - |
| 28.33% |
| - |
| - |
| - |
| - |
| NRX PHARMACEUTICALS, NRX PHARMA, NRX PHARMACEUTICAL |
| 16.10.26 |
|